|
 
 |
| LETTER TO EDITOR |
|
| Year : 2022 | Volume
: 17
| Issue : 4 | Page : 1028 |
|
Serum BDNF in COVID-19 Patients: A Summative Analysis
Beuy Joob1, Viroj Wiwanitkit2
1 Private Academic Practice, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India
| Date of Submission | 21-Mar-2021 |
| Date of Decision | 10-Dec-2021 |
| Date of Acceptance | 16-Dec-2021 |
| Date of Web Publication | 10-Feb-2023 |
Correspondence Address:
Dr. Beuy Joob
Private Academic Practice, Bangkok, Thailand, 13 Academic Center, Bangkok 112
Thailand
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jdmimsu.jdmimsu_121_21
How to cite this article:
Joob B, Wiwanitkit V. Serum BDNF in COVID-19 Patients: A Summative Analysis. J Datta Meghe Inst Med Sci Univ 2022;17:1028 |
Sir,
The COVID-19 is a new coronavirus infection. This infection causes pandemic and results in a worldwide public health problem. The infection manifests as an acute respiratory illness. However, it can also manifest atypical clinical presentation.[1] The neuropsychiatric problem due to COVID-19 is also possible. The pathophysiological process relating to the angiotensin-converting enzyme 2\Mas\BDNF signaling pathway is mentioned.[2] Alteration of serum DNF in COVID-19 patients is an interesting issue in laboratory medicine.[2] There are few reports on serum BDNF determination in COVID-19 patients.[3],[4]
Here, the authors perform a summative analysis for reappraisal on those available data on serum BDNF in COVID-19 patients. From 10 COVID-19 patients (five males and five females; age 7–90 years with average 52.5 ± 18.6 years), the average serum BDNF level is 5265.69 ± 2089.50 pg/mL. Comparing this level to the level in the normal population (range = 32690 ± 8330 pg/mL), the value in COVID-19 is lower. This can confirm the hypothesis that there might be downregulation and decreased expression of BDNF in COVID-19.[2] Further studies on the BDNF level in COVID-19 in a larger sample size and the assessment of clinical association are recommended.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | |  |
| 1. | Tin SS, Wiwanitkit V. Uncommon atypical presentations of COVID-19: Important and should not be under recognized! J Health Sci Med Res 2020;38:153-8.  |
| 2. | Motaghinejad M, Gholami M. Possible neurological and mental outcomes of COVID-19 infection: A hypothetical role of ACE-2\Mas\BDNF signaling pathway. Int J Prev Med 2020;11:84. [Full text] |
| 3. | Azoulay D, Shehadeh M, Chepa S, Shaoul E, Baroum M, Horowitz NA, et al. Recovery from SARS-CoV-2 infection is associated with serum BDNF restoration. J Infect 2020;81:e79-81. |
| 4. | De Paulis M, Oliveira DB, Vieira RP, Pinto IC, Machado RR, Cavalcanti MP, et al. Multisystem inflammatory syndrome associated with COVID-19 with neurologic manifestations in a child: A brief report. Pediatr Infect Dis J 2020;39:e321-4. |
|
Search Pubmed for